{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:13:43Z","timestamp":1786122823198,"version":"build-2736575974"},"reference-count":232,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Endometrial cancer (EC) is characterized by significant molecular and immunological heterogeneity, which influences both disease progression and response to therapy. Although immune checkpoint blockade has improved the clinical management of selected EC subtypes, durable responses remain limited in many patients, particularly in tumors with poorly inflamed or mismatch repair-proficient\/microsatellite-stable profiles. In this context, natural killer (NK) cells represent an important but still insufficiently explored component of anti-tumor immunity. NK cells can recognize transformed or stressed cells independently of antigen-specific priming, which may be relevant in EC tumors characterized by altered antigen presentation, immune exclusion, or limited T-cell responsiveness. Within the EC tumor microenvironment, NK-cell dysfunction is likely shaped by a complex interplay between defective recruitment, altered receptor\u2013ligand interactions, suppressive cytokine networks, and tumor-driven immune remodeling. These mechanisms may reduce NK-cell cytotoxicity and favor immunoregulatory or tolerance-like phenotypes, some of which resemble programs involved in maternal\u2013fetal immune tolerance. Here, we examine how EC may reshape NK-cell recruitment, phenotype, and function, and discuss how these alterations intersect with molecular tumor heterogeneity, immune escape, and emerging NK-directed therapeutic strategies. Particular attention is given to how NK-directed and NK-complementary approaches, including cytokine-based activation, NK-cell engagers, adoptive NK-cell transfer, chimeric antigen receptor natural killer cell (CAR-NK) platforms, and their integration with immune checkpoint blockade, may help address resistance in EC.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1784443","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T12:05:59Z","timestamp":1786104359000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Natural killer cells at the interface of tumor immune escape and immunotherapy resistance in endometrial cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Alessandro","family":"Poggi","sequence":"first","affiliation":[{"name":"Molecular Oncology and Angiogenesis Unit, IRCCS Ospedale Policlinico San Martino","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bruno","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Unit, Department of Experimental Clinical Oncology, IRCCS Regina Elena National Cancer Institute","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Di Spirito","sequence":"additional","affiliation":[{"name":"Immunology and General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria","place":["Varese, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Mortara","sequence":"additional","affiliation":[{"name":"Immunology and General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria","place":["Varese, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denisa","family":"Baci","sequence":"additional","affiliation":[{"name":"Immunology and General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria","place":["Varese, Italy"]},{"name":"Molecular Cardiology Laboratory, IRCCS Policlinico San Donato","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3182605bf1","article-title":"Endometrial cancer","volume":"120","author":"Sorosky","year":"2012","journal-title":"Obstet Gynecol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2023.34.e85","article-title":"FIGO staging of endometrial cancer: 2023","volume":"34","author":"Berek","year":"2023","journal-title":"J Gynecol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-004981","article-title":"FIGO 2023 endometrial cancer staging: too much, too soon","volume":"34","author":"McCluggage","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2012.23.2.120","article-title":"Fertility-sparing treatment of endometrial cancer: options, outcomes and pitfalls","volume":"23","author":"Kesterson","year":"2012","journal-title":"J Gynecol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/GCO.0000000000000186","article-title":"Latest developments and techniques in gynaecological oncology surgery","volume":"27","author":"Soleymani Majd","year":"2015","journal-title":"Curr Opin Obstet Gynecol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813181","article-title":"Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer","volume":"380","author":"Matei","year":"2019","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial","volume":"19","author":"de Boer","year":"2018","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.5952","article-title":"Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study","volume":"35","author":"Ott","year":"2017","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00156","article-title":"Endometrial cancer immune escape mechanisms: let us learn from the fetal-maternal interface","volume":"10","author":"Bruno","year":"2020","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI68107","article-title":"Uterine NK-cells: active regulators at the maternal-fetal interface","volume":"124","author":"Moffett","year":"2014","journal-title":"J Clin Invest"},{"key":"B15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211035959","article-title":"The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer","volume":"13","author":"Jamieson","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Brit J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061467","article-title":"Polymerase epsilon-associated ultramutagenesis in cancer","volume":"14","author":"Xing","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41419-023-06418-3","article-title":"The P286R mutation of DNA polymerase \u03f5 activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway","volume":"15","author":"Tang","year":"2024","journal-title":"Cell Death Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.11.023","article-title":"Polymerase \u03f5 (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro","volume":"144","author":"Bellone","year":"2017","journal-title":"Gynecol Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2020-207281","article-title":"DNA mismatch repair proteins: scientific update and practical guide","volume":"74","author":"Bateman","year":"2021","journal-title":"J Clin Pathol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102175","article-title":"Microsatellite instability in Gastric Cancer: Between lights and shadows","volume":"95","author":"Puliga","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0598","article-title":"Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer","volume":"17","author":"Oaknin","year":"2021","journal-title":"Future Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqy178","article-title":"Immunohistochemical nuclear expression of \u03b2-catenin as a surrogate of CTNNB1 exon 3 mutation in endometrial cancer","volume":"151","author":"Travaglino","year":"2019","journal-title":"Am J Clin Pathol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1581","article-title":"beta-Catenin mutations and aberrant nuclear expression during endometrial tumorigenesis","volume":"84","author":"Saegusa","year":"2001","journal-title":"Br J Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ygyno.2009.09.025","article-title":"Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study","volume":"116","author":"Fleming","year":"2010","journal-title":"Gynecol Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.009","article-title":"Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oaknin","year":"2022","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101685","article-title":"ARID1A deficiency associated with MMR deficiency and a high abundance of tumor-infiltrating lymphocytes predicts a good prognosis of endometrial carcinoma","volume":"33","author":"Sun","year":"2023","journal-title":"Transl Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0012-z","article-title":"ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade","volume":"24","author":"Shen","year":"2018","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.96","article-title":"Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer","volume":"26","author":"Bosse","year":"2013","journal-title":"Mod Pathol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"PO.17.00073","DOI":"10.1200\/PO.17.00073","article-title":"Landscape of microsatellite instability across 39 cancer types","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1035616","article-title":"Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study","volume":"13","author":"Dai","year":"2022","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1586315","article-title":"The immune microenvironment in endometrial carcinoma: mechanisms and therapeutic targeting","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1213347","article-title":"The role of tumor-associated macrophages in the progression, prognosis and treatment of endometrial cancer","volume":"13","author":"Sun","year":"2023","journal-title":"Front Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1165602","article-title":"Loss of NLRP3 reduces oxidative stress and polarizes intratumor macrophages to attenuate immune attack on endometrial cancer","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s12672-025-02169-z","article-title":"Immune microenvironment and molecular mechanisms in endometrial cancer: implications for resistance and innovative treatments","volume":"16","author":"Chen","year":"2025","journal-title":"Discov Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.62347\/BXZM8857","article-title":"Immune cell infiltration as a prognostic factor in endometrial cancer: a meta-analysis","volume":"15","author":"Lin","year":"2025","journal-title":"Am J Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00877","article-title":"Endometrial tumor microenvironment alters human NK cell recruitment, and resident NK cell phenotype and function","volume":"10","author":"Degos","year":"2019","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037555","article-title":"Single-cell transcriptomics reveals comprehensive microenvironment and highlights the dysfunctional state of NK cells in endometrioid carcinoma","volume":"103","author":"Shi","year":"2024","journal-title":"Med (Baltimore)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02414-1","article-title":"The development of innate lymphoid cells","volume":"27","author":"Das","year":"2026","journal-title":"Nat Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.07.017","article-title":"Innate lymphoid cells: 10 years on","volume":"174","author":"Vivier","year":"2018","journal-title":"Cell"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0206-4","article-title":"Human NK cells: surface receptors, inhibitory checkpoints, and translational applications","volume":"16","author":"Sivori","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.cell.2020.02.029","article-title":"SnapShot: natural killer cells","volume":"180","author":"Crinier","year":"2020","journal-title":"Cell"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039170","article-title":"Dendritic cell editing by activated natural killer cells results in a more protective cancer-specific immune response","volume":"7","author":"Morandi","year":"2012","journal-title":"PLoS One"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3775","article-title":"DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for anti-tumor CTL induction","volume":"106","author":"Adam","year":"2005","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28932","article-title":"CD40-independent natural killer-cell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma","volume":"135","author":"H\u00f6mberg","year":"2014","journal-title":"Int J Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2015.10.001","article-title":"Bench to bedside: NK cells and control of metastasis","volume":"177","author":"Krasnova","year":"2017","journal-title":"Clin Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1012356108","article-title":"Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK-cells as rapid producers of abundant IFN-gamma on activation","volume":"108","author":"De Maria","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01883-0","article-title":"High-dimensional single-cell analysis of human natural killer cell heterogeneity","volume":"25","author":"Rebuffet","year":"2024","journal-title":"Nat Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/nm1452","article-title":"Decidual NK-cells regulate key developmental processes at the human fetal-maternal interface","volume":"12","author":"Hanna","year":"2006","journal-title":"Nat Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jri.2010.11.002","article-title":"Decidualization and angiogenesis in early pregnancy: unravelling the functions of DC and NK-cells","volume":"88","author":"Blois","year":"2011","journal-title":"J Reprod Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.immuni.2018.03.030","article-title":"Trained memory of human uterine NK-cells enhances their function in subsequent pregnancies","volume":"48","author":"Gamliel","year":"2018","journal-title":"Immunity"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.728291","article-title":"Role of decidual natural killer cells in human pregnancy and related pregnancy complications","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dey001","article-title":"Endometrial natural killer (NK) cells reveal a tissue-specific receptor repertoire","volume":"33","author":"Feyaerts","year":"2018","journal-title":"Hum Reprod"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00170","article-title":"Heterogeneity of NK-cells and other innate lymphoid cells in human and murine decidua","volume":"10","author":"Vacca","year":"2019","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.immuni.2017.11.018","article-title":"Natural killer cells promote fetal development through the secretion of growth-promoting factors","volume":"47","author":"Fu","year":"2017","journal-title":"Immunity"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1353556","article-title":"NK-cell receptor profiling of endometrial and decidual NK-cells reveals pregnancy-induced adaptations","volume":"15","author":"Feyaerts","year":"2024","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1158\/2159-8290.CD-20-0796","article-title":"Decidual-like NK-cell polarization: From cancer killing to cancer nurturing","volume":"11","author":"Albini","year":"2021","journal-title":"Cancer Discov"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0406250","article-title":"Expression of angiogenic growth factors by uterine natural killer cells during early pregnancy","volume":"80","author":"Lash","year":"2006","journal-title":"J Leukoc Biol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1593\/neo.121758","article-title":"The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer","volume":"15","author":"Bruno","year":"2013","journal-title":"Neoplasia"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.821542","article-title":"Human-induced CD49a+ NK-cells promote fetal growth","volume":"13","author":"Du","year":"2022","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00131","article-title":"Orchestration of angiogenesis by immune cells","volume":"4","author":"Bruno","year":"2014","journal-title":"Front Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2438598","article-title":"Natural killer cells from Malignant pleural effusion are endowed with a decidual-like proangiogenic polarization","volume":"2018","author":"Bosi","year":"2018","journal-title":"J Immunol Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201701103R","article-title":"Angiogenin and the MMP9-TIMP2 axis are up-regulated in proangiogenic, decidual NK-like cells from patients with colorectal cancer","volume":"32","author":"Bruno","year":"2018","journal-title":"FASEB J"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00527","article-title":"Contribution to tumor angiogenesis from innate immune cells within the tumor microenvironment: Implications for immunotherapy","volume":"9","author":"Albini","year":"2018","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11040461","article-title":"Natural killer cells as key players of tumor progression and angiogenesis: Old and novel tools to divert their pro-tumor activities into potent anti-tumor effects","volume":"11","author":"Bassani","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00771","article-title":"Myeloid derived suppressor cells interactions with natural killer cells and pro-angiogenic activities: Roles in tumor progression","volume":"10","author":"Bruno","year":"2019","journal-title":"Front Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27654","article-title":"Renal cell tumors convert natural killer cells to a proangiogenic phenotype","volume":"11","author":"Guan","year":"2020","journal-title":"Oncotarget"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.586126","article-title":"Prostate cancer peripheral blood NK-cells show enhanced CD9, CD49a, CXCR4, CXCL8, MMP-9 production and secrete monocyte-recruiting and polarizing factors","volume":"11","author":"Gallazzi","year":"2021","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/cells10030614","article-title":"Intratumor regulatory noncytotoxic NK-cells in patients with hepatocellular carcinoma","volume":"10","author":"Zecca","year":"2021","journal-title":"Cells"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3390\/cells10071621","article-title":"Angiogenic properties of NK-cells in cancer and other angiogenesis-dependent diseases","volume":"10","author":"Radomska-Le\u015bniewska","year":"2021","journal-title":"Cells"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00490","article-title":"The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity","volume":"4","author":"Baginska","year":"2013","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3962","article-title":"The tumor microenvironment innately modulates cancer progression","volume":"79","author":"Hinshaw","year":"2019","journal-title":"Cancer Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108374","article-title":"Crosstalk between macrophages and natural killer cells in the tumor microenvironment","volume":"101","author":"Zhou","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-\u03b2 signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"key":"B83","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41568-021-00413-6","article-title":"Overcoming TGFbeta-mediated immune evasion in cancer","volume":"22","author":"Tauriello","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"B84","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","article-title":"TGFbeta biology in cancer progression and immunotherapy","volume":"18","author":"Derynck","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01685","article-title":"The roles of glycodelin in cancer development and progression","volume":"8","author":"Cui","year":"2017","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1111\/aji.12471","article-title":"The pleiotropic effect of glycodelin-A in early pregnancy","volume":"75","author":"Lee","year":"2016","journal-title":"Am J Reprod Immunol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12958-017-0303-0","article-title":"TGFbeta superfamily signaling and uterine decidualization","volume":"15","author":"Ni","year":"2017","journal-title":"Reprod Biol Endocrinol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0611098104","article-title":"TGFbeta promotes conversion of CD16+ peripheral blood NK-cells into CD16- NK-cells with similarities to decidual NK-cells","volume":"104","author":"Keskin","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200939910","article-title":"TGF-beta affects development and differentiation of human natural killer cell subsets","volume":"40","author":"Allan","year":"2010","journal-title":"Eur J Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202582","article-title":"Conversion of peripheral blood NK-cells to a decidual NK-like phenotype by a cocktail of defined factors","volume":"190","author":"Cerdeira","year":"2013","journal-title":"J Immunol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/humrep\/dey378","article-title":"Glycodelin-A stimulates the conversion of human peripheral blood CD16-CD56bright NK-cell to a decidual NK-cell-like phenotype","volume":"34","author":"Lee","year":"2019","journal-title":"Hum Reprod"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.932055","article-title":"Lactate from the tumor microenvironment - A key obstacle in NK cell-based immunotherapies","volume":"13","author":"Jedli\u010dka","year":"2022","journal-title":"Front Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26383","article-title":"Tumor-derived lactate and myeloid-derived suppressor cells: Linking metabolism to cancer immunology","volume":"2","author":"Husain","year":"2013","journal-title":"Oncoimmunology"},{"key":"B94","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1186\/s12967-025-06235-6","article-title":"Metabolic interplay between endometrial cancer and tumor-associated macrophages: lactate-induced M2 polarization enhances tumor progression","volume":"23","author":"Liu","year":"2025","journal-title":"J Transl Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071733","article-title":"Exosomes on endometrial cancer: A biomarkers treasure trove","volume":"14","author":"Sykaras","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2026.121061","article-title":"Harnessing exosomes for endometrial cancer: From non-invasive diagnostics to precision therapies","volume":"590","author":"Saleh","year":"2026","journal-title":"Clin Chim Acta"},{"key":"B97","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12943-019-0991-5","article-title":"Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance","volume":"18","author":"Mashouri","year":"2019","journal-title":"Mol Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030473","article-title":"The interplay of exosomes and NK cells in cancer biology","volume":"13","author":"Batista","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.565666","article-title":"Circulating extracellular vesicles in gynecological tumors: Realities and challenges","volume":"10","author":"Herrero","year":"2020","journal-title":"Front Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22042165","article-title":"Exosomes as biomarkers for female reproductive diseases diagnosis and therapy","volume":"22","author":"Esfandyari","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1448204","article-title":"Editorial: Hypoxia and angiogenesis in cancer","volume":"15","author":"Malekan","year":"2024","journal-title":"Front Pharmacol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.17195","article-title":"Hypoxia-induced factor-1\u03b1 and its role in endometrial cancer","volume":"44","author":"Smolarz","year":"2024","journal-title":"Anticancer Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.587420","article-title":"Prognostic and clinicopathological significance of hypoxia-inducible factor-1\u03b1 in endometrial cancer: a meta-analysis","volume":"10","author":"Zhu","year":"2020","journal-title":"Front Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.924775","article-title":"NK cells under hypoxia: The two faces of vascularization in tumor and pregnancy","volume":"13","author":"Garc\u00e9s-L\u00e1zaro","year":"2022","journal-title":"Front Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.09.008","article-title":"The prognostic benefit of tumour-infiltrating natural killer cells in endometrial cancer is dependent on concurrent overexpression of human leucocyte antigen-E in the tumour microenvironment","volume":"86","author":"Versluis","year":"2017","journal-title":"Eur J Cancer"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26491","article-title":"Role of non-classical MHC class I molecules in cancer immunosuppression","volume":"2","author":"Kochan","year":"2013","journal-title":"Oncoimmunology"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.ccell.2022.08.005","article-title":"NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer","volume":"40","author":"Salom\u00e9","year":"2022","journal-title":"Cancer Cell"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091570","article-title":"Reduced HLA-I transcript levels and increased abundance of a CD56dim NK-cell signature are associated with improved survival in lower-grade gliomas","volume":"17","author":"Al Kamran Khan","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-9-184","article-title":"High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis","volume":"9","author":"Benevolo","year":"2011","journal-title":"J Transl Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.11.002","article-title":"Recent advances in cytomegalovirus: An update on pharmacologic and cellular therapies","volume":"21","author":"Boeckh","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2015.09.003","article-title":"HLA-E regulates NKG2C+ natural killer cell function through presentation of a restricted peptide repertoire","volume":"76","author":"Lauterbach","year":"2015","journal-title":"Hum Immunol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0802736105","article-title":"Structural basis for NKG2A\/CD94 recognition of HLA-E","volume":"105","author":"Kaiser","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/18.15.4250","article-title":"Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94\/NKG2-A and the activating receptor CD94\/NKG2-C to HLA-E","volume":"18","author":"Val\u00e9s-G\u00f3mez","year":"1999","journal-title":"EMBO J"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2010.07.011","article-title":"The other Janus face of Qa-1 and HLA-E: Diverse peptide repertoires in times of stress","volume":"12","author":"van Hall","year":"2010","journal-title":"Microbes Infect"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1525924","article-title":"Association between human leukocyte antigen E expression and outcomes in solid tumors: A systematic review and meta-analysis","volume":"15","author":"Fuentes","year":"2025","journal-title":"Front Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0483","article-title":"Inhibition of MICA and MICB shedding elicits NK-cell-mediated immunity against tumors resistant to cytotoxic T cells","volume":"8","author":"Ferrari de Andrade","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174311","article-title":"Single-cell profiling of the immune atlas of tumor-infiltrating lymphocytes in endometrial carcinoma","volume":"14","author":"Jiang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1433_4153","DOI":"10.4049\/jimmunol.212.supp.1433.4153","article-title":"Natural killer cells display unique, non-cytotoxic profiles in human endometrial cancer","volume":"212","author":"Eisele","year":"2024","journal-title":"J Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2020.03.008","article-title":"Expression analysis of immune-regulatory molecules HLA-G, HLA-E and IDO in endometrial cancer","volume":"81","author":"Ben Yahia","year":"2020","journal-title":"Hum Immunol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4144","article-title":"Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: Its association with disease progression and survival","volume":"14","author":"Ino","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2016.3631","article-title":"Cancer-associated fibroblast suppresses killing activity of natural killer cells through downregulation of poliovirus receptor (PVR\/CD155), a ligand of activating NK receptor","volume":"49","author":"Inoue","year":"2016","journal-title":"Int J Oncol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.neo.2017.11.003","article-title":"Rapamycin synergizes with cisplatin in antiendometrial cancer activation by improving IL-27\u2013stimulated cytotoxicity of NK-cells","volume":"20","author":"Zhou","year":"2018","journal-title":"Neoplasia"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3390\/futurepharmacol2040039","article-title":"Chasing uterine cancer with NK-cell-based immunotherapies","volume":"2","author":"Kumar","year":"2022","journal-title":"Future Pharmacol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0140-6736(25)00553-7","article-title":"Cancer vaccines and the future of immunotherapy","volume":"406","author":"Pail","year":"2025","journal-title":"Lancet"},{"key":"B125","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","article-title":"Advances in cancer immunotherapy: Historical perspectives, current developments, and future directions","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol Cancer"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152666","article-title":"Immunotherapy in cancer","author":"Zeiser","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-024-02568-2","article-title":"Immunotherapy for endometrial cancer","volume":"30","author":"Wada","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: Update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14041385","article-title":"Comprehensive review of endometrial cancer: New molecular and FIGO classification and recent treatment changes","volume":"14","author":"Anca-Stanciu","year":"2025","journal-title":"J Clin Med"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26188789","article-title":"The efficacy of pembrolizumab immunotherapy in the treatment of endometrial cancer: A systematic review","volume":"26","author":"Picheta","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102701","article-title":"Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis","volume":"125","author":"Bartoletti","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.934493","article-title":"Efficacy of PD-1 inhibitor combined with bevacizumab in treatment of advanced endometrial cancer patients with mismatch repair deficiency (dMMR)\/high-level microsatellite instability (MSI-H)","volume":"28","author":"Liao","year":"2022","journal-title":"Med Sci Monit"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003777","article-title":"Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient\/microsatellite instability-high (dMMR\/MSI-H) or proficient\/stable (MMRp\/MSS) endometrial cancer: Interim results from GARNET-a phase I, single-arm study","volume":"10","author":"Oaknin","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-003675","article-title":"Immunotherapy in endometrial cancer","volume":"33","author":"Mahdi","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01825","article-title":"Natural killer cell-based immunotherapy in gynecologic Malignancy: A review","volume":"8","author":"Uppendahl","year":"2018","journal-title":"Front Immunol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0686","article-title":"Distinct mechanisms of mismatch-repair deficiency delineate two modes of response to anti-PD-1 immunotherapy in endometrial carcinoma","volume":"13","author":"Chow","year":"2023","journal-title":"Cancer Discov"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1658580","article-title":"Signaling intact membrane-bound IL-15 enables potent anti-tumor activity and safety of CAR-NK-cells","volume":"16","author":"Xu","year":"2025","journal-title":"Front Immunol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1574742","article-title":"CAR-NK-cell therapy: Promise and challenges in solid tumors","volume":"16","author":"Balkhi","year":"2025","journal-title":"Front Immunol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2025.2556714","article-title":"Anti-FAP CAR-NK cells as a novel targeted therapy against cervical cancer and cancer-associated fibroblasts","volume":"14","author":"Polten","year":"2025","journal-title":"Oncoimmunology"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.70210","article-title":"CAR-NK, a splendid strategy for cancer, especially for gynecologic tumor","volume":"13","author":"Cao","year":"2025","journal-title":"Immun Inflammation Dis"},{"key":"B142","doi-asserted-by":"publisher","first-page":"6081","DOI":"10.1016\/j.cell.2021.11.016","article-title":"An NK-like CAR T cell transition in CAR T cell dysfunction","volume":"184","author":"Good","year":"2021","journal-title":"Cell"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1361194","article-title":"CAR-NK-cells for cancer immunotherapy: Recent advances and future directions","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12885-025-13590-6","article-title":"The PENDOR study: Establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors","volume":"25","author":"Le Gall","year":"2025","journal-title":"BMC Cancer"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-024-01703-z","article-title":"Proteogenomic insights into early-onset endometrioid endometrial carcinoma: Predictors for fertility-sparing therapy response","volume":"56","author":"Hu","year":"2024","journal-title":"Nat Genet"},{"key":"B146","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12943-024-02039-2","article-title":"Multi-omics profiling reveal cells with novel oncogenic cluster, TRAP1low\/CAMSAP3low, emerge more aggressive behavior and poor-prognosis in early-stage endometrial cancer","volume":"23","author":"Mao","year":"2024","journal-title":"Mol Cancer"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"B148","doi-asserted-by":"publisher","first-page":"5417","DOI":"10.1038\/s41467-023-41132-w","article-title":"Systematic transcriptional analysis of human cell lines for gene expression landscape and tumor representation","volume":"14","author":"Jin","year":"2023","journal-title":"Nat Commun"},{"key":"B149","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41467-019-11415-2","article-title":"Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types","volume":"10","author":"Yu","year":"2019","journal-title":"Nat Commun"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.15422","article-title":"Advances in the use of organoids in endometrial diseases","volume":"166","author":"Liu","year":"2024","journal-title":"Int J Gynaecol Obstet"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-019-0360-z","article-title":"Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening","volume":"21","author":"Boretto","year":"2019","journal-title":"Nat Cell Biol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.21769\/BioProtoc.5093","article-title":"Generation and maintenance of patient-derived endometrial cancer organoids","volume":"14","author":"Barbi","year":"2024","journal-title":"Bio Protoc"},{"key":"B153","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s00018-025-05807-5","article-title":"Organoids as powerful models of endometrium epithelium in transcriptomic, cellular and functional mimicry","volume":"82","author":"Ciprietti","year":"2025","journal-title":"Cell Mol Life Sci"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18111692","article-title":"The role of mesothelin in gynecological tumors and its significance in targeted therapies - a review","volume":"18","author":"Kawecka","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1705354","article-title":"CAR-NK cell for gynecological cancers: immune microenvironment remodeling and immunotherapeutic strategies","volume":"16","author":"Huang","year":"2025","journal-title":"Front Immunol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.725330","article-title":"Engineered T cell therapy for gynecologic Malignancies: challenges and opportunities","volume":"12","author":"Xu","year":"2021","journal-title":"Front Immunol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ygyno.2023.03.008","article-title":"HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis","volume":"172","author":"Bruce","year":"2023","journal-title":"Gynecol Oncol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.3390\/cimb45040220","article-title":"The current status and future perspectives of chimeric antigen receptor-engineered T cell therapy for the management of patients with endometrial cancer","volume":"45","author":"Choi","year":"2023","journal-title":"Curr Issues Mol Biol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.11.028","article-title":"CAR T cells targeting MISIIR for the treatment of ovarian cancer and other gynecologic Malignancies","volume":"28","author":"Rodriguez-Garcia","year":"2020","journal-title":"Mol Ther"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2019.30.e46","article-title":"Immunotherapy in endometrial cancer: new scenarios on the horizon","volume":"30","author":"Di Tucci","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2006.07.003","article-title":"Human natural killer lymphocytes through the engagement of natural cytotoxicity receptors and NKG2D can trigger self-aggression","volume":"6","author":"Poggi","year":"2007","journal-title":"Autoimmun Rev"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.10.6352","article-title":"Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors","volume":"175","author":"Poggi","year":"2005","journal-title":"J Immunol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.3390\/biom12091303","article-title":"Co-stimulatory receptor signaling in CAR-T cells","volume":"12","author":"Honikel","year":"2022","journal-title":"Biomolecules"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1384039","article-title":"Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges","volume":"15","author":"Kong","year":"2024","journal-title":"Front Immunol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1738378","article-title":"Prospects and challenges for use of CAR T cell therapies in solid tumors","volume":"20","author":"Ramakrishna","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.07.016","article-title":"Rationally designed redirection of natural killer cells anchoring a cytotoxic ligand for pancreatic cancer treatment","volume":"326","author":"Lee","year":"2020","journal-title":"J Control Release"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0137-8","article-title":"Gene editing for immune cell therapies","volume":"37","author":"Bailey","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01965","article-title":"Use of cell and genome modification technologies to generate improved off-the-shelf CAR T and CAR NK cells","volume":"11","author":"Morgan","year":"2020","journal-title":"Front Immunol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1675807","article-title":"Beyond CAR-T cells: exploring CAR-NK, CAR-M, and CAR-gamma-delta T strategies in solid tumor immunotherapy","volume":"16","author":"Hou","year":"2025","journal-title":"Front Immunol"},{"key":"B171","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40164-026-00746-8","article-title":"Stem cell engineering for the generation of allogeneic CAR-directed natural killer T cells targeting endometrial carcinoma","volume":"15","author":"Li","year":"2026","journal-title":"Exp Hematol Oncol"},{"key":"B172","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1016\/j.ccell.2025.09.013","article-title":"Engineered natural killer cells for cancer therapy","volume":"43","author":"Biederstadt","year":"2025","journal-title":"Cancer Cell"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2013.10","article-title":"NK cell-based immunotherapy for Malignant diseases","volume":"10","author":"Cheng","year":"2013","journal-title":"Cell Mol Immunol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.3109\/14653249.2012.700767","article-title":"Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications","volume":"14","author":"Lapteva","year":"2012","journal-title":"Cytotherapy"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.219","article-title":"Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2\/HER2-specific chimeric antigen receptor","volume":"23","author":"Schonfeld","year":"2015","journal-title":"Mol Ther"},{"key":"B176","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/s41591-023-02770-1","article-title":"Author correction: KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape","volume":"30","author":"Li","year":"2024","journal-title":"Nat Med"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.886319","article-title":"DNAM-1-chimeric receptor-engineered NK cells, combined with Nutlin-3a, more effectively fight neuroblastoma cells in vitro: a proof-of-concept study","volume":"13","author":"Focaccetti","year":"2022","journal-title":"Front Immunol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1197053","article-title":"DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy","volume":"14","author":"Cifaldi","year":"2023","journal-title":"Front Immunol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2908284","article-title":"New insights into the potential role of chimeric activating receptors in natural killer cell-based immunotherapy","volume":"29","author":"Cifaldi","year":"2024","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172917","article-title":"Expanding immunotherapy beyond CAR T cells: engineering diverse immune cells to target solid tumors","volume":"17","author":"Andreou","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2024.02.04","article-title":"Hypoxic tumor microenvironment: destroyer of natural killer cell function","volume":"36","author":"Zhang","year":"2024","journal-title":"Chin J Cancer Res"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0231-4","article-title":"Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1\/CXCR4 axis","volume":"9","author":"Teng","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.10.474","article-title":"Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial","volume":"32","author":"Hiltbrunner","year":"2021","journal-title":"Ann Oncol"},{"key":"B184","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1182\/blood-2024-204369","article-title":"Mesothelin targeting IL12-engineered CAR memory-like NK cells demonstrate promising efficacy in acute myeloid leukemia","volume":"144","author":"Jang","year":"2024","journal-title":"Blood"},{"key":"B185","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12943-024-02184-8","article-title":"Chimeric antigen receptor macrophages targeting c-MET (CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy","volume":"23","author":"Zheng","year":"2024","journal-title":"Mol Cancer"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2023.120","article-title":"The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer","volume":"7","author":"Martinez-Cannon","year":"2024","journal-title":"Cancer Drug Resist"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115329","article-title":"Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: a systematic review and network meta-analysis","volume":"220","author":"Villacampa","year":"2025","journal-title":"Eur J Cancer"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1159\/000541617","article-title":"Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or tyrosine kinase inhibitors in advanced endometrial cancer: a systematic review and meta-analysis","volume":"90","author":"Li","year":"2025","journal-title":"Gynecol Obstet Invest"},{"key":"B189","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12905-025-03612-7","article-title":"Efficacy comparison of PD-1\/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis","volume":"25","author":"Ji","year":"2025","journal-title":"BMC Womens Health"},{"key":"B190","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.seminoncol.2023.09.005","article-title":"PARP inhibitors: a review of the pharmacology, pharmacokinetics, and pharmacogenetics","volume":"51","author":"Zeng","year":"2024","journal-title":"Semin Oncol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115893","article-title":"Molecular classification of endometrial cancer and its impact on therapy selection","volume":"25","author":"Galant","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.844801","article-title":"How immunotherapy modified the therapeutic scenario of endometrial cancer: a systematic review","volume":"12","author":"Maiorano","year":"2022","journal-title":"Front Oncol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104555","article-title":"First-line treatments for advanced or recurrent endometrial cancer: systematic literature review of clinical evidence","volume":"206","author":"Mirza","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14020401","article-title":"PD-1 and PD-L1 expression in endometrial cancer: a systematic review of the literature","volume":"14","author":"De Tommasi","year":"2025","journal-title":"J Clin Med"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1571800","article-title":"Global research trends and focus on immunotherapy for endometrial cancer: a comprehensive bibliometric insight and visualization analysis (2012-2024)","volume":"16","author":"Xu","year":"2025","journal-title":"Front Immunol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3915","article-title":"Safety, efficacy, and biomarker analyses of dostarlimab in patients with endometrial cancer: interim results of the phase I GARNET study","volume":"29","author":"Oaknin","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology\/GOG0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J Clin Oncol"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01326","article-title":"First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: a randomized, open-label, phase III trial","volume":"43","author":"Marth","year":"2025","journal-title":"J Clin Oncol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2516891","article-title":"Treatment patterns and outcomes by mismatch repair\/microsatellite instability status among patients with primary advanced or recurrent endometrial cancer in the United States","volume":"21","author":"Chase","year":"2025","journal-title":"Future Oncol"},{"key":"B200","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jaci.2016.04.025","article-title":"Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization","volume":"139","author":"Pesce","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00167","article-title":"NK cell-based immune checkpoint inhibition","volume":"11","author":"Khan","year":"2020","journal-title":"Front Immunol"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1172\/JCI99317","article-title":"Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade","volume":"128","author":"Hsu","year":"2018","journal-title":"J Clin Invest"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add1187","article-title":"Successful targeting of PD-1\/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model","volume":"8","author":"Liu","year":"2022","journal-title":"Sci Adv"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1111\/sji.13250","article-title":"Identification of tumour antigens and immune subtypes in the development of an anti-cancer vaccine for endometrial carcinoma","volume":"97","author":"Feng","year":"2023","journal-title":"Scand J Immunol"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225801","article-title":"A personalized neoantigen vaccine in combination with platinum-based chemotherapy induces a T-cell response coinciding with a complete response in endometrial carcinoma","volume":"13","author":"Harari","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ado6491","article-title":"Identification of immunogenic HLA class I and II neoantigens using surrogate immunopeptidomes","volume":"10","author":"Tokita","year":"2024","journal-title":"Sci Adv"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1645371","article-title":"Immunotherapy for high-grade endometrial stromal sarcoma: a narrative review bridging molecular insights to clinical translation","volume":"16","author":"Zhao","year":"2025","journal-title":"Front Immunol"},{"key":"B208","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.cell.2020.01.026","article-title":"Proteogenomic characterization of endometrial carcinoma","volume":"180","author":"Dou","year":"2020","journal-title":"Cell"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1528532","article-title":"Unveiling immunogenic characteristics and neoantigens in endometrial cancer with POLE hotspot mutations for improved immunotherapy","volume":"16","author":"Huang","year":"2025","journal-title":"Front Immunol"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1709968","article-title":"First FDA approval agnostic of cancer site - when a biomarker defines the indication","volume":"377","author":"Lemery","year":"2017","journal-title":"N Engl J Med"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105954","article-title":"DNA methylation mediates the immunosuppressive tumour microenvironment in metastatic endometrial clear cell carcinoma","volume":"120","author":"Jia","year":"2025","journal-title":"EBioMedicine"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26157151","article-title":"Feasibility of manufacturing and antitumor activity of TIL for advanced endometrial cancers","volume":"26","author":"Zhang","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2064711","article-title":"Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions","volume":"22","author":"Granh\u00f8j","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005443","article-title":"Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer","volume":"10","author":"Palomero","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71023","article-title":"Tumor-infiltrating lymphocytes in breast and female genital tract cancers: overlooked potential and unexplored frontiers","volume":"14","author":"Skok","year":"2025","journal-title":"Cancer Med"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00984-x","article-title":"Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach","volume":"22","author":"de Rodas","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104471","article-title":"Advancements in tumor-infiltrating lymphocytes: historical insights, contemporary milestones, and future directions in oncology therapy","volume":"202","author":"Aizaz","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B218","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ygyno.2013.11.010","article-title":"Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer","volume":"132","author":"Liu","year":"2014","journal-title":"Gynecol Oncol"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.01.009","article-title":"Oncolytic vaccinia virotherapy for endometrial cancer","volume":"132","author":"Liu","year":"2014","journal-title":"Gynecol Oncol"},{"key":"B220","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12985-018-0975-x","article-title":"Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines","volume":"15","author":"Lin","year":"2018","journal-title":"Virol J"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1055\/a-2618-6935","article-title":"Infecting cancer to cure it: the power of oncolytic viruses in gynecologic oncology - a narrative review","volume":"75","author":"Kumar","year":"2025","journal-title":"Drug Res (Stuttg)"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.3390\/cells12141838","article-title":"Developing oncolytic viruses for the treatment of cervical cancer","volume":"12","author":"Kalafati","year":"2023","journal-title":"Cells"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13080880","article-title":"Oncolytic herpes simplex virus therapy: latest advances, core challenges, and future outlook","volume":"13","author":"Zheng","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2025.06.006","article-title":"CAR-NK-cells to treat patients with cancer: a systematic scoping review of published studies and registered clinical trials","volume":"27","author":"Rana","year":"2025","journal-title":"Cytotherapy"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115123","article-title":"IPSC-derived CAR-NK-cells for cancer immunotherapy","volume":"165","author":"Lin","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B226","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adt9932","article-title":"Robust differentiation of NK-cells from MSLN.CAR-IL-15-engineered human iPSCs with enhanced antitumor efficacy against solid tumors","volume":"11","author":"Jiang","year":"2025","journal-title":"Sci Adv"},{"key":"B228","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1186\/s13287-025-04461-9","article-title":"Human iPSC-derived NK-cells armed with CCL19, CCR2B, high-affinity CD16, IL-15, and NKG2D complex enhance anti-solid tumor activity","volume":"16","author":"Fukutani","year":"2025","journal-title":"Stem Cell Res Ther"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.561553","article-title":"Umbilical cord blood and iPSC-derived natural killer cells demonstrate key differences in cytotoxic activity and KIR profiles","volume":"11","author":"Goldenson","year":"2020","journal-title":"Front Immunol"},{"key":"B230","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omto.2021.11.016","article-title":"Natural killer cells and immune-checkpoint inhibitor therapy: current knowledge and new challenges","volume":"24","author":"Poggi","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3493","article-title":"TGF-\u03b2 inhibits the activation and functions of NK-cells by repressing the mTOR pathway","volume":"17","author":"Viel","year":"2016","journal-title":"Nat Immunol"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-025-11163-1","article-title":"Generation of the augmented IL-15-secreting anti-HER2 chimeric antigen receptor (CAR)-NK-cells: an encouraging immunotherapeutic tool","volume":"53","author":"Darvishvand","year":"2025","journal-title":"Mol Biol Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1784443\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T12:06:02Z","timestamp":1786104362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1784443\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":232,"alternative-id":["10.3389\/fimmu.2026.1784443"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1784443","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"article-number":"1784443"}}